Our top pick for
Verona Pharma plc is a biotechnology business based in the US. Verona Pharma shares (VRNA) are listed on the NASDAQ and all prices are listed in US Dollars. Verona Pharma employs 33 staff and has a market cap (total outstanding shares value) of USD$322 million.
|Latest market close||USD$7.9|
|52-week range||USD$2.01 - USD$9.5|
|50-day moving average||USD$6.338|
|200-day moving average||USD$6.2506|
|Wall St. target price||USD$18.8|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-2.336|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-06)||N/A|
|1 month (2020-12-13)||N/A|
|3 months (2020-10-13)||N/A|
|6 months (2020-07-13)||N/A|
|1 year (2020-01-13)||N/A|
|2 years (2019-01-13)||N/A|
|3 years (2018-01-13)||N/A|
|5 years (2016-01-13)||N/A|
|Gross profit TTM||USD$0|
|Return on assets TTM||-22.5%|
|Return on equity TTM||-41.82%|
|Market capitalisation||USD$322 million|
TTM: trailing 12 months
There are currently 56,946 Verona Pharma shares held short by investors – that's known as Verona Pharma's "short interest". This figure is 27.5% down from 78,577 last month.
There are a few different ways that this level of interest in shorting Verona Pharma shares can be evaluated.
Verona Pharma's "short interest ratio" (SIR) is the quantity of Verona Pharma shares currently shorted divided by the average quantity of Verona Pharma shares traded daily (recently around 103538.18181818). Verona Pharma's SIR currently stands at 0.55. In other words for every 100,000 Verona Pharma shares traded daily on the market, roughly 550 shares are currently held short.
However Verona Pharma's short interest can also be evaluated against the total number of Verona Pharma shares, or, against the total number of tradable Verona Pharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Verona Pharma's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Verona Pharma shares in existence, roughly 0 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable Verona Pharma shares, roughly 0 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Verona Pharma.
Find out more about how you can short Verona Pharma stock.
We're not expecting Verona Pharma to pay a dividend over the next 12 months.
Over the last 12 months, Verona Pharma's shares have ranged in value from as little as $2.01 up to $9.5. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Verona Pharma's is 0.418. This would suggest that Verona Pharma's shares are less volatile than average (for this exchange).
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on develops and commercializes therapies for the treatment of respiratory diseases with unmet medical needs. Its product candidate, ensifentrine (RPL554), is an inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 that acts as both a bronchodilator and an anti-inflammatory agent in a single compound. The formulations of ensifentrine are under development for the treatment chronic obstructive pulmonary disease (COPD): nebulized ensifentrine is in Phase 2b clinical development for the maintenance treatment of COPD; and a dry powder inhaler and a pressurized metered-dose inhaler. The company also focuses on developing ensifentrine for the treatment of cystic fibrosis and asthma. Verona Pharma plc was founded in 2005 and is headquartered in London, the United Kingdom.
Everything we know about the CDT Environmental Technology Investment Holdings Limited IPO, plus information on how to buy in.
Everything we know about the Viant Technology Inc IPO, plus information on how to buy in.
Steps to owning and managing EVGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing ETL, with 24-hour and historical pricing before you buy.
Steps to owning and managing EQBK, with 24-hour and historical pricing before you buy.
Steps to owning and managing EIGI, with 24-hour and historical pricing before you buy.
Steps to owning and managing ELTK, with 24-hour and historical pricing before you buy.
Steps to owning and managing DNKN, with 24-hour and historical pricing before you buy.
Steps to owning and managing DKL, with 24-hour and historical pricing before you buy.
Steps to owning and managing DMAC, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.